Search 

YDS Medicine, Inc. (referred to as “YDS”) provides computational drug discovery services. Through our proprietary self-learning AI drug discovery system, YDS is assisting pharma and biotech companies to reduce their drug discovery cost by at least 20% while doing it 10X faster and increasing success rate by at least 20%.

YDS is endeavoring to decrease the cost of drug discovery, especially in the lead discovery and optimization stages. To decrease such trial-and-error costs at these stages, YDS shifts the knowledge-based process to a self-learning process. The AI+biophysics system developed at YDS is able to optimize chemical molecules towards desired biophysical/chemical properties, serving as GPS for the drug discovery journey.

focus on CVD, oncology，immunology

healthcare VC

Yonghua Capital is an institutional investor, with headquarter in Shanghai and portfolio overseas. We have invested in over 40 companies in healthcare field over past 5 years.

Leading life science venture capital firm investing in pre-clinical or early clinical stage.

Project assessment, auditing, project management, regulatory affairs, quality, and IP management services

the developer and investor of zhangjiang scientific city

2nd market PE,
about 300M RMB total value,
mainly focus on A-share market and startup on H-share market,
concentrating on high-speed developing industrials especially in Healthcare, including Big Biopharma/Superior Biotech companies.

Zhejiang Jianfeng Pharmaceutical Co., Ltd., founded on Dec. 30th, 1998, is a wholly-owned subsidiary of listed company Zhejiang Jianfeng Group Co., Ltd. (SHA: 600668). 　　Our company consists of five industrial enterprises, three commercial enterprises, three scientific institutions and two mobile postdoctoral stations. It is one of National Top 100 Pharmaceutical Enterprises, one of Top 10 Pharmaceutical Industrial Enterprises of Zhejiang Province, National Key High-tech Enterprise, National high-tech Industrialization Demonstration Project Enterprise, Innovative Demonstration Enterprise of Zhejiang Province, and AAA-level Contract-honoring and Promise-keeping Enterprise of Zhejiang Province.

Our key products include Aspartic Acid Amlodipine Tablets, Aceclofenac Sustained-release Tablets, Paroxetine Hydrochloride Tablets, Cefmenoxime Hydrochloride for Injection, Yufeng Ningxin Drop Pills, Penciclovir for Injection, Sodium Hyaluronate Eye Drops, and etc.

Adhering to the corporate spirit of “Aiming for Top One, Producing Fine Medicine”, pursuing business philosophy of “science and technology achieve health”, our company has been oriented by the development of bulk pharmaceutical chemicals with high technology content and high-added value, and new chemical medicine preparations and aided by the natural products extraction and proprietary Chinese medicine preparations. Meanwhile, our company is paying attention to the development method of new biological agent medicine, and will enter into the health product field in good time. We now have a main line with three major series products, which are anti-infection medicine, cardiovascular medicine, and anti-depression medicine. Depending on first-rate business philosophy, first-rate production management and first-rate products, our company will create a famous brand that is trusted by the public, and contribute to the health of human.

a stock company in China. Focus on the high quality finish product according to cGMP.